These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 11086020)

  • 1. The mechanisms of estrogen regulation of bone resorption.
    Riggs BL
    J Clin Invest; 2000 Nov; 106(10):1203-4. PubMed ID: 11086020
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL inhibitors: a bright future?
    Roux S
    Joint Bone Spine; 2006 Mar; 73(2):129-31. PubMed ID: 16488648
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.
    Hofbauer LC; Heufelder AE
    Eur J Endocrinol; 1998 Aug; 139(2):152-4. PubMed ID: 9724069
    [No Abstract]   [Full Text] [Related]  

  • 6. Bone resorption by osteoclasts.
    Teitelbaum SL
    Science; 2000 Sep; 289(5484):1504-8. PubMed ID: 10968780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKing the importance of measles virus in Paget's disease.
    Ross FP
    J Clin Invest; 2000 Mar; 105(5):555-8. PubMed ID: 10712423
    [No Abstract]   [Full Text] [Related]  

  • 8. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transduction pathways regulating osteoclast differentiation and function.
    Tanaka S; Nakamura I; Inoue J; Oda H; Nakamura K
    J Bone Miner Metab; 2003; 21(3):123-33. PubMed ID: 12720046
    [No Abstract]   [Full Text] [Related]  

  • 10. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.
    Horowitz MC; Xi Y; Wilson K; Kacena MA
    Cytokine Growth Factor Rev; 2001 Mar; 12(1):9-18. PubMed ID: 11312114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [[From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin?].
    Bénard J
    Bull Cancer; 2000 Sep; 87(9):623-4. PubMed ID: 11184451
    [No Abstract]   [Full Text] [Related]  

  • 13. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.
    Haynes DR; Crotti TN; Potter AE; Loric M; Atkins GJ; Howie DW; Findlay DM
    J Bone Joint Surg Br; 2001 Aug; 83(6):902-11. PubMed ID: 11521937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK, RANKL and osteoprotegerin in arthritic bone loss.
    Bezerra MC; Carvalho JF; Prokopowitsch AS; Pereira RM
    Braz J Med Biol Res; 2005 Feb; 38(2):161-70. PubMed ID: 15785827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.
    Cenci S; Weitzmann MN; Roggia C; Namba N; Novack D; Woodring J; Pacifici R
    J Clin Invest; 2000 Nov; 106(10):1229-37. PubMed ID: 11086024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
    Stajszczyk M
    Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
    [No Abstract]   [Full Text] [Related]  

  • 19. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
    Kostenuik PJ
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.